Charles Duncan
Stock Analyst at Cantor Fitzgerald
(4.10)
# 521
Out of 4,918 analysts
226
Total ratings
43.32%
Success rate
15.49%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Reiterates: Overweight | n/a | $4.35 | - | 6 | Mar 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Overweight | $28 | $23.53 | +19.00% | 21 | Feb 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $140 → $150 | $115.52 | +29.85% | 6 | Feb 26, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $153 | $103.02 | +48.51% | 22 | Feb 19, 2025 | |
| GHRS GH Research | Initiates: Overweight | $14 | $13.91 | +0.65% | 1 | Feb 13, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Overweight | n/a | $33.63 | - | 1 | Jan 10, 2025 | |
| BHVN Biohaven | Reiterates: Overweight | n/a | $14.71 | - | 17 | Dec 17, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $12.91 | - | 7 | Dec 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $34.38 | +68.73% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $26.55 | +61.96% | 5 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $36.69 | - | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.84 | - | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $128.91 | +20.24% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $13.21 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $13.43 | +160.61% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $4.19 | +210.26% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.56 | - | 6 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.67 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.44 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.17 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $21.12 | +60.98% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $27.84 | +79.60% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $6.83 | -26.79% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.36 | +1,024.23% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.00 | +300.00% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $30.48 | +90.29% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $1,100 | $5.98 | +18,294.65% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $3.49 | +2,192.26% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.38 | +117.39% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $11.19 | -1.70% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $7.88 | +52.28% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $6.56 | +2,460.98% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.14 | +834.58% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $14.58 | +1,272.21% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $0.50 | +700.00% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $2.13 | +1,029.41% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $1.43 | +9,969.93% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.17 | +241.88% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $59.02 | -33.92% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $69.00 | -78.26% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $0.56 | - | 3 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $3.61 | +4,886.15% | 1 | Oct 9, 2017 |
COMPASS Pathways
Mar 28, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.35
Upside: -
ACADIA Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $28
Current: $23.53
Upside: +19.00%
Jazz Pharmaceuticals
Feb 26, 2025
Downgrades: Neutral
Price Target: $140 → $150
Current: $115.52
Upside: +29.85%
Axsome Therapeutics
Feb 19, 2025
Reiterates: Overweight
Price Target: $153
Current: $103.02
Upside: +48.51%
GH Research
Feb 13, 2025
Initiates: Overweight
Price Target: $14
Current: $13.91
Upside: +0.65%
Bright Minds Biosciences
Jan 10, 2025
Initiates: Overweight
Price Target: n/a
Current: $33.63
Upside: -
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.71
Upside: -
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $12.91
Upside: -
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $34.38
Upside: +68.73%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $26.55
Upside: +61.96%
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $36.69
Upside: -
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.84
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $128.91
Upside: +20.24%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.21
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $13.43
Upside: +160.61%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $4.19
Upside: +210.26%
Jul 31, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.56
Upside: -
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.67
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.44
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.17
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $21.12
Upside: +60.98%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $27.84
Upside: +79.60%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $6.83
Upside: -26.79%
Sep 7, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.36
Upside: +1,024.23%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $1.00
Upside: +300.00%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $30.48
Upside: +90.29%
Aug 22, 2023
Reiterates: Overweight
Price Target: $1,100
Current: $5.98
Upside: +18,294.65%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $3.49
Upside: +2,192.26%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.38
Upside: +117.39%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $11.19
Upside: -1.70%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $7.88
Upside: +52.28%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $6.56
Upside: +2,460.98%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $2.14
Upside: +834.58%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $14.58
Upside: +1,272.21%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $0.50
Upside: +700.00%
Oct 23, 2020
Initiates: Overweight
Price Target: $24
Current: $2.13
Upside: +1,029.41%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $1.43
Upside: +9,969.93%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $1.17
Upside: +241.88%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $59.02
Upside: -33.92%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $69.00
Upside: -78.26%
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $0.56
Upside: -
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $3.61
Upside: +4,886.15%